期刊文献+

CA125结合人附睾分泌蛋白4检验诊断卵巢癌的价值

The Value of CA125 Combined with Human Epididymal Secretory Protein 4 Test in Diagnosing Ovarian Cancer
下载PDF
导出
摘要 目的研究分析糖类抗原125(CA125)结合人附睾分泌蛋白4(HE4)检验诊断卵巢癌的价值。方法选取2019年1月—2022年3月在扬州市江都人民医院治疗的60例卵巢癌患者设为研究组,选取同期收治的60例卵巢良性肿瘤患者设为对照组。对两组患者CA125、HE4水平进行检测,统计对比检测结果。结果研究组患者CA125、HE4水平均高于对照组患者,差异有统计学意义(P<0.05)。在研究组中,Ⅲ~Ⅳ期患者CA125、HE4水平均高于Ⅰ~Ⅱ期患者,差异有统计学意义(P<0.05)。在研究组中,有淋巴转移患者CA125、HE4水平分别为(412.03±86.59)kU/L、(372.36±86.75)pmol/L,均高于无淋巴转移患者,差异有统计学意义(t=15.046、7.636,P<0.05)。CA125结合HE4诊断卵巢癌的特异度、灵敏度、准确度、阴性预测值、阳性预测值均高于CA125与HE4单项诊断,差异有统计学意义(P<0.05)。结论在卵巢癌诊断中,CA125结合HE4检验的临床价值更高,能够精准判定患者病情,为患者治疗提供指导依据。 Objective To study and analyze the value of carbohydrate antigen 125(CA125)combined with human epi⁃didymal secretory protein 4(HE4)test for the diagnosis of ovarian cancer.Methods From January 2019 to March 2022,60 patients with ovarian cancer treated in Yangzhou Jiangdu People's Hospital were selected as the study group,and 60 patients with benign ovarian tumors admitted in the same period were selected as the control group.The levels of CA125 and HE4 in the two groups were detected,and the results were statistically compared.Results The levels of CA125 and HE4 in the study group were higher than those in the control group,and the difference was statistically sig⁃nificant(P<0.05).In the study group,the levels of CA125 and HE4 in patients with stageⅢ-Ⅳwere higher than those in patients with stageⅠ-Ⅱ,and the difference was statistically significant(P<0.05).In the study group,the levels of CA125 and HE4 in patients with lymph node metastasis were(412.03±86.59)kU/L and(372.36±86.75)pmol/L,re⁃spectively,which were higher than those in patients without lymph node metastasis,and the difference was statistically significant(t=15.046,7.636,P<0.05).The specificity,sensitivity,accuracy,negative predictive value and positive pre⁃dictive value of CA125 combined with HE4 in the diagnosis of ovarian cancer were higher than those of CA125 and HE4 alone,and the difference was statistically significant(P<0.05).Conclusion In the diagnosis of ovarian cancer,the clinical value of CA125 combined with HE4 test is higher,which can accurately determine the patient's condition and provide guidance basis for patient treatment,and is worthy of clinical recommendation and application.
作者 邵大祥 李绪文 SHAO Daxiang;LI Xuwen(Department of Laboratory,Yangzhou Jiangdu People's Hospital,Yangzhou,Jiangsu Province,225200 China)
出处 《系统医学》 2023年第1期10-14,共5页 Systems Medicine
关键词 卵巢癌 糖类抗原125 人附睾分泌蛋白4 诊断价值 Ovarian cancer Carbohydrate antigen 125 Human epithelial secretory protein 4 Diagnostic value
  • 相关文献

参考文献14

二级参考文献136

  • 1张欣,吴令英,李晓江,李洪君,张蓉,刘丽影.盆腔良性肿物伴血清CA_(125)水平升高的临床意义[J].中华妇产科杂志,2005,40(3):178-182. 被引量:65
  • 2李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 3Jacobs I J, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics, 2004, 3 : 355- 366.
  • 4Bast RC Jr, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res, 2007, 174:91-100.
  • 5Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2006, 4:912-939.
  • 6Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res, 2004, 10:3919-3926.
  • 7Hellstrom I, Raycraft J, Hayden-Ledbetter, et al. The HE4 (WFIXE) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003, 63 : 3695 -3700.
  • 8Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol, 2008, 110 : 374-382.
  • 9Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 2008, 108:402-408.
  • 10Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 2009, 112: 40-46.

共引文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部